Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2023-173413

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Aplastic Anemia: Insight from a Single Center Experience

Parth C. Patel, Najla H Al Ali, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Kendra Sweet, Alison R. Walker, Jeffrey Lancet, David A Sallman, Michael V. Jaglal, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2023-178952

Published: 2023

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Somedeb Ball, Avani M Singh, Najla Al Ali, Luis E. Aguirre, Akriti G Jain, Zaker I. Schwabkey, Sara M Tinsley-Vance, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 1118–1120.

https://doi.org/10.1182/blood-2022-170158

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chen Wang, Onyee Chan, Najla Al Ali, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 6936–6937.

https://doi.org/10.1182/blood-2022-160464

Published: 2022

Journal Articles

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Rami S. Komrokji, Najla Al Ali, Somedeb Ball, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 4039–4041.

https://doi.org/10.1182/blood-2022-169690

Published: 2022

Journal Articles

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Zaker I. Schwabkey, Amin Azem, Najla Al Ali, Somedeb Ball, Luis E. Aguirre, Akriti G Jain, Avani M Singh, Sara M Tinsley-Vance, Onyee Chan, Jeffrey E. Lancet, Kendra Sweet, Andrew Kuykendall, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 6974–6975.

https://doi.org/10.1182/blood-2022-156974

Published: 2022

Journal Articles

Discordance between Patient Goals and Treatment in Older AML Patients

Sara Marie Tinsley-Vance, Cecile A. Lengacher, Andrew Kuykendall, Daniel Lastorino, Amaya Oyola, Onyee Chan, Eric Padron, Areej El-Jawahri, David A. Sallman, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 8133–8135.

https://doi.org/10.1182/blood-2022-163684

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Avani M Singh, Akriti G Jain, Onyee Chan, Zaker I. Schwabkey, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 1125–1127.

https://doi.org/10.1182/blood-2022-170878

Published: 2022

Journal Articles

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Michael Mauro, Alexis Visotcky, Kathryn E Flynn, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Jorge E. Cortes, Vamsi K Kota, Srinivas K. Tantravahi, Arielle Baim, Mei-Jie Zhang, Alexander Hinman, Ehab L. Atallah, Kendra Sweet

Blood (2022) 140 (Supplement 1): 6765–6766.

https://doi.org/10.1182/blood-2022-160138

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

Somedeb Ball, Akriti G Jain, Parth C. Patel, Chen Wang, Luis E. Aguirre, Mohammad O Hussaini, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 6282–6284.

https://doi.org/10.1182/blood-2022-170442

Published: 2022

Journal Articles

The Impact of Chronic Kidney Disease on Hospitalization Outcomes in Patients Admitted with Acute Myeloid Leukemia: A Nationwide Analysis Using the National Inpatient Sample Database (2015-2019)

Mohammad Ammad Ud Din, Kendra Sweet

Blood (2022) 140 (Supplement 1): 6056–6057.

https://doi.org/10.1182/blood-2022-170891

Published: 2022

Journal Articles

Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Arlene A. Gayle, Stuart J. Kahn, Eric Padron, Jeffrey E. Lancet, Andrew Kuykendall, Kendra Sweet, Onyee Chan, Dean Y. Maeda, Aaron D. Schuler, John A. Zebala, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 2070–2072.

https://doi.org/10.1182/blood-2022-159774

Published: 2022

Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Blood (2022) 140 (Supplement 1): 11026–11028.

https://doi.org/10.1182/blood-2022-159615

Published: 2022

NARROW

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Aplastic Anemia: Insight from a Single Center Experience

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Discordance between Patient Goals and Treatment in Older AML Patients

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

The Impact of Chronic Kidney Disease on Hospitalization Outcomes in Patients Admitted with Acute Myeloid Leukemia: A Nationwide Analysis Using the National Inpatient Sample Database (2015-2019)

Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only